Erysipelothrix rhusiopathiae cDNA and Antigen

Erysipelothrix rhusiopathiae is a Gram-positive, non-spore-forming, rod-shaped bacterium, which is the causative agent of erysipelas, a severe skin infection. It is found in soil, water and on the surface of animals, and is often associated with the fish and poultry industries. It is a facultative anaerobe and is an important cause of disease in both humans and animals. The bacterium is resistant to many antibiotics, including penicillin and tetracycline. Infection is most seen in humans in the form of skin lesions but can also cause systemic disease in immunocompromised individuals. This bacterium has several antigens, including:

Surface protective antigens SpaB and SpaC: These antigens are surface proteins that are involved in adhesion to host cells and protection against the host immune system. They are potential targets for vaccine development.

60 kDa chaperonin: This protein is a molecular chaperone that helps with protein folding and stabilization. It has been identified as an immunodominant antigen in E. rhusiopathiae infections and has been proposed as a potential vaccine candidate.

Cell wall surface anchor family antigen: This antigen is a cell wall-associated protein that is involved in adhesion to host cells. It has been shown to be important for bacterial virulence in animal models of infection.

These antigens are potential targets for the development of vaccines or diagnostic tools for E. rhusiopathiae infections. By targeting these antigens, it may be possible to stimulate an immune response that is effective in preventing or treating infection. Additionally, these antigens may be useful as diagnostic markers to identify the presence of E. rhusiopathiae in clinical samples.

Overall, understanding the role of these antigens in E. rhusiopathiae pathogenesis is important for the development of effective treatments and diagnostic tools for this bacterial infection.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

These applications of recombinant proteins/cDNA are:

Identification and characterization of virulence factors: The cDNA of E. rhusiopathiae can be used to study the expression of genes involved in virulence and antibiotic resistance. This information can aid in the development of new treatments for infections caused by this bacterium.

Diagnostic tests: Recombinant antigens of E. rhusiopathiae can be used as target antigens in diagnostic tests such as ELISA (Enzyme-linked Immunosorbent Assay) for the detection of infections caused by this bacterium in animals.

Vaccine development: The recombinant antigens of E. rhusiopathiae can be used as potential vaccine targets to protect animals against infections caused by this bacterium.

Antibiotic resistance studies: The cDNA of E. rhusiopathiae can be used to study the expression of genes involved in antibiotic resistance, which can help in the development of new antibiotics to combat antibiotic-resistant strains of this bacterium.

These are just a few examples of the applications of E. rhusiopathiae cDNA and recombinant antigen. Further research in this field can lead to the development of new and effective treatments for infections caused by this bacterium in animals and humans.